Published in Proc Natl Acad Sci U S A on February 03, 2010
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
Lipoproteins of bacterial pathogens. Infect Immun (2010) 1.73
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine (2012) 1.71
Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing information. J Clin Microbiol (2012) 1.49
Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev (2013) 1.49
Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol (2012) 1.29
Meningococcal disease and the complement system. Virulence (2013) 1.19
Proteinaceous determinants of surface colonization in bacteria: bacterial adhesion and biofilm formation from a protein secretion perspective. Front Microbiol (2013) 1.15
Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. MBio (2014) 1.13
Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine (2011) 1.11
Comparative genome biology of a serogroup B carriage and disease strain supports a polygenic nature of meningococcal virulence. J Bacteriol (2010) 1.08
Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis (2013) 1.01
Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med (2013) 1.01
Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years. J Clin Microbiol (2014) 1.00
Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii. J Bacteriol (2012) 1.00
Conservation of meningococcal antigens in the genus Neisseria. MBio (2013) 0.98
Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses? Clin Vaccine Immunol (2013) 0.98
Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. Infect Immun (2012) 0.96
New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers. Indian J Med Res (2013) 0.96
An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. PLoS One (2013) 0.96
Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol (2014) 0.93
Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine. Clin Vaccine Immunol (2015) 0.92
Genomic Epidemiology of Hypervirulent Serogroup W, ST-11 Neisseria meningitidis. EBioMedicine (2015) 0.90
Comparative proteome analysis of spontaneous outer membrane vesicles and purified outer membranes of Neisseria meningitidis. J Bacteriol (2013) 0.89
Neisseria meningitidis NalP cleaves human complement C3, facilitating degradation of C3b and survival in human serum. Proc Natl Acad Sci U S A (2013) 0.88
Prevalence and phase variable expression status of two autotransporters, NalP and MspA, in carriage and disease isolates of Neisseria meningitidis. PLoS One (2013) 0.84
Phase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage. Infect Immun (2014) 0.83
Structure of the C-terminal domain of Neisseria heparin binding antigen (NHBA), one of the main antigens of a novel vaccine against Neisseria meningitidis. J Biol Chem (2011) 0.83
Genomic and global approaches to unravelling how hypermutable sequences influence bacterial pathogenesis. Pathogens (2014) 0.82
Opc expression, LPS immunotype switch and pilin conversion contribute to serum resistance of unencapsulated meningococci. PLoS One (2012) 0.82
Slam is an outer membrane protein that is required for the surface display of lipidated virulence factors in Neisseria. Nat Microbiol (2016) 0.80
Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant. PLoS One (2015) 0.80
A naturally occurring single-residue mutation in the translocator domain of Neisseria meningitidis NhhA affects trimerization, surface localization, and adhesive capabilities. Infect Immun (2011) 0.79
Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine Against Genetically Diverse Serogroup B Meningococci. Clin Vaccine Immunol (2016) 0.79
The Long Road to an Effective Vaccine for Meningococcus Group B (MenB). Ann Med Surg (Lond) (2013) 0.78
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection. Ther Adv Vaccines (2015) 0.78
How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines. J Immunol Res (2015) 0.77
Evaluation of anticoagulants for serologic assays of cholera vaccination. Clin Vaccine Immunol (2014) 0.77
Expression of the Gene for Autotransporter AutB of Neisseria meningitidis Affects Biofilm Formation and Epithelial Transmigration. Front Cell Infect Microbiol (2016) 0.77
1H, 13C and 15N assignment of the C-terminal domain of GNA2132 from Neisseria meningitidis. Biomol NMR Assign (2010) 0.76
In-silico prediction and deep-DNA sequencing validation indicate phase variation in 115 Neisseria meningitidis genes. BMC Genomics (2016) 0.76
Molecular characterization of invasive capsule null Neisseria meningitidis in South Africa. BMC Microbiol (2017) 0.75
Impact of Moderate Temperature Changes on Neisseria meningitidis Adhesion Phenotypes and Proteome. Infect Immun (2016) 0.75
Epitope Mapping of a Monoclonal Antibody Directed against Neisserial Heparin Binding Antigen Using Next Generation Sequencing of Antigen-Specific Libraries. PLoS One (2016) 0.75
Meningococcal B Vaccination (4CMenB) in Infants and Toddlers. J Immunol Res (2015) 0.75
Interstrain Cooperation in Meningococcal Biofilms: Role of Autotransporters NalP and AutA. Front Microbiol (2017) 0.75
Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States. Ther Adv Vaccines (2017) 0.75
Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009. F1000Res (2014) 0.75
The Phosphocarrier Protein HPr Contributes to Meningococcal Survival during Infection. PLoS One (2016) 0.75
Neisserial Heparin Binding Antigen (NHBA) Contributes to the Adhesion of Neisseria meningitidis to Human Epithelial Cells. PLoS One (2016) 0.75
Heparin Mimics Extracellular DNA in Binding to Cell Surface-Localized Proteins and Promoting Staphylococcus aureus Biofilm Formation. mSphere (2017) 0.75
The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C. Vaccine (2017) 0.75
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 7.41
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet (2007) 5.11
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev (1991) 3.93
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
Microbial adherence to and invasion through proteoglycans. Infect Immun (1997) 3.22
Heparin and heparan sulfate: structure and function. Nat Prod Rep (2002) 2.85
Functional significance of factor H binding to Neisseria meningitidis. J Immunol (2006) 2.39
Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol (1996) 2.30
Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med (1996) 2.18
Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology (2002) 2.17
Localization of the heparin-binding site on complement factor H. J Biol Chem (1991) 1.77
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis (2003) 1.73
Conquering the meningococcus. FEMS Microbiol Rev (2007) 1.73
Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis (2009) 1.67
Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine (2006) 1.67
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine (2009) 1.58
A Neisserial autotransporter NalP modulating the processing of other autotransporters. Mol Microbiol (2003) 1.56
Sulfated glycoconjugate receptors for the Bordetella pertussis adhesin filamentous hemagglutinin (FHA) and mapping of the heparin-binding domain on FHA. Infect Immun (1994) 1.54
Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol (2005) 1.51
Autotransported serine protease A of Neisseria meningitidis: an immunogenic, surface-exposed outer membrane, and secreted protein. Infect Immun (2002) 1.36
Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol (2009) 1.32
Intimate adhesion of Neisseria meningitidis to human epithelial cells is under the control of the crgA gene, a novel LysR-type transcriptional regulator. EMBO J (2000) 1.30
Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol (2009) 1.24
Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim Biophys Acta (2005) 1.22
Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. Infect Immun (1999) 1.21
Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine (2005) 1.19
Neisseria meningitidis producing the Opc adhesin binds epithelial cell proteoglycan receptors. Mol Microbiol (1998) 1.18
Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol (2008) 1.13
Heparin protects Opa+ Neisseria gonorrhoeae from the bactericidal action of normal human serum. Infect Immun (1995) 1.07
Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine (2009) 1.05
Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol (1993) 1.04
Enhanced bacterial virulence through exploitation of host glycosaminoglycans. Mol Microbiol (2002) 1.03
Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc Natl Acad Sci U S A (1998) 1.03
Progress towards the development of new vaccines against whooping cough. Vaccine (1992) 1.02
Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. Mol Microbiol (2003) 1.02
Analysis of transcriptional control mechanisms of capsule expression in Neisseria meningitidis. Int J Med Microbiol (2001) 0.97
The minimum information about a genome sequence (MIGS) specification. Nat Biotechnol (2008) 31.04
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A (2005) 14.59
The microbial pan-genome. Curr Opin Genet Dev (2005) 5.93
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A (2002) 5.28
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Microbiology in the post-genomic era. Nat Rev Microbiol (2008) 4.88
Characterization of encapsulated and noncapsulated Haemophilus influenzae and determination of phylogenetic relationships by multilocus sequence typing. J Clin Microbiol (2003) 4.47
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Pili in gram-positive pathogens. Nat Rev Microbiol (2006) 4.21
Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis (2008) 3.98
Genome analysis reveals pili in Group B Streptococcus. Science (2005) 3.85
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
Cytokinins determine Arabidopsis root-meristem size by controlling cell differentiation. Curr Biol (2007) 3.25
c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol (2002) 3.20
Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 3.11
Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol (2006) 3.03
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
A genetic framework for the control of cell division and differentiation in the root meristem. Science (2008) 2.95
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species. Genome Biol (2010) 2.60
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med (2011) 2.59
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A (2009) 2.41
Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microbes Infect (2002) 2.37
A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med (2005) 2.35
The rate of cell differentiation controls the Arabidopsis root meristem growth phase. Curr Biol (2010) 2.33
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J (2011) 2.33
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun (2008) 2.29
Reverse vaccinology: developing vaccines in the era of genomics. Immunity (2010) 2.25
Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med (2010) 2.21
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A (2003) 2.17
Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol (2006) 2.16
CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol (2008) 2.09
Fur functions as an activator and as a repressor of putative virulence genes in Neisseria meningitidis. Mol Microbiol (2004) 2.08
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol (2005) 2.06
Influenza vaccine immunology. Immunol Rev (2011) 2.02
Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis (2008) 2.00
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 1.94
Auxin regulates Arabidopsis anther dehiscence, pollen maturation, and filament elongation. Plant Cell (2008) 1.92
Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. Vaccine (2010) 1.91
Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A (2011) 1.84
Intraclonal variations among Streptococcus pneumoniae isolates influence the likelihood of invasive disease in children. J Infect Dis (2013) 1.84
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One (2009) 1.82
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog (2010) 1.81
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 1.75
Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology (2006) 1.75
Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun (2006) 1.74
Vaccine manufacturing: challenges and solutions. Nat Biotechnol (2006) 1.73
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis (2003) 1.73
Interactions between Neisseria meningitidis and the complement system. Trends Microbiol (2007) 1.72
A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol (2008) 1.72